Clare Meernik, Frances Wang, Yadurshini Raveendran, Michelle F Green, Devon K Check, Hayden B Bosworth, Linda M Sutton, John H Strickler, Tomi F Akinyemiju
{"title":"北卡罗来纳州一家综合癌症中心的种族和民族与基因组检测的关系。","authors":"Clare Meernik, Frances Wang, Yadurshini Raveendran, Michelle F Green, Devon K Check, Hayden B Bosworth, Linda M Sutton, John H Strickler, Tomi F Akinyemiju","doi":"10.1158/2767-9764.CRC-24-0134","DOIUrl":null,"url":null,"abstract":"<p><strong>Significance: </strong>Non-Hispanic Black patients diagnosed with prostate cancer between 2014 and 2019 and treated at a comprehensive cancer center were less likely to use tumor-specific genomic testing compared with non-Hispanic White patients. Disparities in the use of precision oncology technologies should be monitored and addressed to ensure equitable cancer care.</p>","PeriodicalId":72516,"journal":{"name":"Cancer research communications","volume":" ","pages":"2968-2975"},"PeriodicalIF":2.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11570879/pdf/","citationCount":"0","resultStr":"{\"title\":\"Association of Race and Ethnicity with Genomic Testing at a Comprehensive Cancer Center in North Carolina.\",\"authors\":\"Clare Meernik, Frances Wang, Yadurshini Raveendran, Michelle F Green, Devon K Check, Hayden B Bosworth, Linda M Sutton, John H Strickler, Tomi F Akinyemiju\",\"doi\":\"10.1158/2767-9764.CRC-24-0134\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Significance: </strong>Non-Hispanic Black patients diagnosed with prostate cancer between 2014 and 2019 and treated at a comprehensive cancer center were less likely to use tumor-specific genomic testing compared with non-Hispanic White patients. Disparities in the use of precision oncology technologies should be monitored and addressed to ensure equitable cancer care.</p>\",\"PeriodicalId\":72516,\"journal\":{\"name\":\"Cancer research communications\",\"volume\":\" \",\"pages\":\"2968-2975\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11570879/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer research communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/2767-9764.CRC-24-0134\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer research communications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2767-9764.CRC-24-0134","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
基因组检测通过分析肿瘤细胞或循环肿瘤 DNA 来指导癌症治疗，在精准肿瘤学中的应用越来越广泛。然而，有关其使用中的种族和民族差异的数据却很有限。这项回顾性队列研究纳入了 2014-2019 年诊断为 IV 期乳腺癌、结直肠癌、非小细胞肺癌或前列腺癌的患者。研究人员从机构多层次数据仓库中识别出患者，并将他们的数据与机构基因组学数据库和电子健康记录连接起来。多变量逻辑回归用于估计非西班牙裔（NH）黑人和NH白人患者接受肿瘤特异性基因组检测的几率比（ORs）和95%置信区间（CIs），并按癌症类型进行分层。链接数据集包括 3461 名患者，其中 44.5% 接受了基因组检测。在整个研究期间，前列腺癌的新罕布什尔州黑人患者与新罕布什尔州白人患者相比不太可能使用基因组检测（完全调整后的OR：0.55，95% CI：0.32，0.95），2014-2016年诊断为乳腺癌的新罕布什尔州黑人患者也是如此（根据患者水平协变量调整后的OR：0.34，95% CI：0.11，0.99）。在 2017-2019 年确诊的结直肠癌、非小细胞肺癌或乳腺癌患者中，没有观察到新罕布什尔州黑人和新罕布什尔州白人在检测方面的差异。在整个研究期间，有记录的新罕布什尔州黑人前列腺癌患者中肿瘤特异性基因组检测的使用率较低，这凸显了监测趋势和解决新兴精准肿瘤学技术使用差异的必要性。未来针对基因组检测的多层次障碍开展工作是向前迈进的关键一步。
Association of Race and Ethnicity with Genomic Testing at a Comprehensive Cancer Center in North Carolina.
Significance: Non-Hispanic Black patients diagnosed with prostate cancer between 2014 and 2019 and treated at a comprehensive cancer center were less likely to use tumor-specific genomic testing compared with non-Hispanic White patients. Disparities in the use of precision oncology technologies should be monitored and addressed to ensure equitable cancer care.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
